MilliporeSigma, Genetix Pact to Scale Life-Changing Gene Therapies

BURLINGTON, MA – May 07, 2026 – In a significant move to solidify the commercial pipeline for some of the world's most advanced medicines, MilliporeSigma has entered into a five-year exclusive agreement with Genetix Biotherapeutics. The deal makes MilliporeSigma the sole provider of analytical and biosafety release testing for Genetix's entire portfolio of three FDA-approved gene therapies, a critical step in scaling access to one-time curative treatments for devastating rare diseases.

The partnership underscores the intricate and vital infrastructure required to bring gene therapies from the clinical trial stage to widespread commercial availability. The agreement covers Genetix's transformative therapies: LYFGENIA™ for sickle cell disease, ZYNTEGLO™ for β-thalassemia, and SKYSONA® for cerebral adrenoleukodystrophy (CALD). These treatments, which involve genetically modifying a patient's own cells, represent a paradigm shift in medicine but rely heavily on a foundation of rigorous, reliable testing to ensure their safety and efficacy.

“As cell and gene therapies continue to move into commercial use as treatments for devastating diseases, this agreement underscores the critical role our high-quality BioReliance® analytical and biosafety testing plays,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany.

A Critical Partnership for Curative Therapies

For patients suffering from conditions like sickle cell disease, which affects over 100,000 Americans, the promise of a one-time curative therapy is life-altering. Genetix Biotherapeutics, the commercial-stage entity spun out of bluebird bio's pioneering work, has brought three such therapies to market. LYFGENIA™ and ZYNTEGLO™ are ex-vivo lentiviral vector (LVV) therapies that add a functional gene to a patient's own blood stem cells, aiming to eliminate the painful vaso-occlusive events of sickle cell disease and the need for chronic blood transfusions in β-thalassemia, respectively. SKYSONA® offers a similar lifeline, working to slow the relentless neurologic decline in young boys with CALD.

However, the complexity of these treatments cannot be overstated. Each dose is a unique, living medicine created for a single patient. This necessitates an exceptionally stringent testing regimen to guarantee identity, purity, potency, and, above all, safety. The process involves confirming the genetic modification was successful, ensuring the cells are viable, and screening for any adventitious agents like viruses or bacteria that could have been introduced during manufacturing.

This is where MilliporeSigma's role becomes indispensable. As the sole testing provider, the company will perform the end-to-end analytical and biosafety release testing required by the FDA before a therapy can be administered. This partnership allows Genetix to focus on scaling its operations with the confidence that a world-class testing infrastructure is in place.

“That requires a testing partner with deep technical expertise, proven commercial-scale execution and broad geographical reach,” noted Brian Riley, President and Chief Technical Officer of Genetix Biotherapeutics. “Sharing a patient-centric mindset makes MilliporeSigma a natural fit as we work together to deliver one-time curative therapies reliably and consistently to patients who need them most.”

Solidifying Leadership in a Booming Market

The agreement is a significant strategic victory for MilliporeSigma, positioning it as a dominant force in the crucial, high-growth market for gene therapy support services. The global gene therapy market is expanding rapidly, with projections estimating it could surpass $40 billion by 2032. As the FDA anticipates approving 10 to 20 new cell and gene therapies annually, the demand for specialized contract testing, development, and manufacturing services is exploding.

In this competitive landscape, which includes major players like Charles River Laboratories and Thermo Fisher Scientific, MilliporeSigma's exclusive deal with Genetix is a powerful statement. It leverages the company's decades-long leadership in biopharmaceutical testing, embodied by its BioReliance® services portfolio. With over 75 years of specialized expertise, MilliporeSigma offers a comprehensive suite of cGMP-compliant services, from viral clearance studies to advanced genetic stability assays using its proprietary Aptegra® platform.

By securing a long-term, sole-provider contract for an entire portfolio of commercially approved therapies, MilliporeSigma not only guarantees a steady revenue stream but also deepens its expertise and reinforces its reputation as the go-to partner for companies navigating the final, most complex stages of drug commercialization.

A Decade of Collaboration Fuels Commercial Success

This landmark five-year agreement was not forged overnight. It is the culmination of more than a decade of close collaboration between the two companies. Long before Genetix's therapies reached commercial stage, its scientists were working alongside MilliporeSigma's experts to jointly develop and validate the highly specialized test methods needed for these novel treatments. This long-standing relationship built a foundation of trust and shared technical understanding that is rare and invaluable in the fast-moving biotech industry.

Such deep integration is crucial for a field where manufacturing processes are still evolving and regulatory goalposts can shift. The ability to work with a partner who intimately understands the history, science, and specific challenges of a product provides a significant competitive advantage. It streamlines communication, accelerates problem-solving, and de-risks the incredibly complex supply chain. The partnership demonstrates a successful model for how therapy innovators and service providers can co-evolve, moving from early-stage development to full-scale commercialization as a unified team.

Navigating the Accessibility and Regulatory Maze

Despite the scientific triumph that these therapies represent, their path to patients is fraught with challenges. The regulatory landscape, overseen by the FDA, demands meticulous adherence to Good Manufacturing Practices (GMP) and a battery of tests to ensure product consistency and safety. This agreement helps Genetix navigate that complex maze by outsourcing the testing to a proven specialist.

A more formidable barrier, however, is cost. With price tags ranging from $2.2 million to over $3 million per patient, accessibility remains a major concern. While this partnership does not directly address pricing, it is a critical component of the accessibility equation. Ensuring a safe, reliable, and scalable supply of these therapies is a prerequisite for any effort to lower costs or expand reimbursement. Any disruption in manufacturing or failure in quality control could set back patient access for months or years. By creating a stable and robust testing framework, MilliporeSigma and Genetix are building the dependable foundation upon which broader access initiatives, such as the CMS Cell and Gene Therapy Access Model for sickle cell disease, can be built.

Ultimately, the agreement represents a maturation of the gene therapy industry. It signals a shift from a focus on pure discovery to the establishment of the robust, industrial-scale infrastructure needed to make these medical miracles a sustainable reality for the patients who await them.